CHARCOT-MARIE-TOOTH DISEASE TYPE-1A - ASSOCIATION WITH A SPONTANEOUS POINT MUTATION IN THE PMP22 GENE

被引:303
|
作者
ROA, BB
GARCIA, CA
SUTER, U
KULPA, DA
WISE, CA
MUELLER, J
WELCHER, AA
SNIPES, GJ
SHOOTER, EM
PATEL, PI
LUPSKI, JR
机构
[1] BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030
[2] BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030
[3] BAYLOR COLL MED,CTR HUMAN GENOME,HOUSTON,TX 77030
[4] LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT NEUROL,NEW ORLEANS,LA 70112
[5] LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT PATHOL,NEW ORLEANS,LA 70112
[6] STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305
[7] STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROPATHOL,STANFORD,CA 94305
[8] SWISS FED INST TECHNOL,DEPT CELL BIOL,CH-8093 ZURICH,SWITZERLAND
来源
NEW ENGLAND JOURNAL OF MEDICINE | 1993年 / 329卷 / 02期
关键词
D O I
10.1056/NEJM199307083290205
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy. CMT type 1A is associated with a 1.5-megabase (Mb) DNA duplication in region p11.2-p12 of chromosome 17 in most patients. An increased dosage of a gene within the duplicated segment appears to cause the disease. The PMP22 gene, which encodes a myelin protein, has been mapped within the duplication and proposed as a candidate gene for CMT type 1A. Methods. We analyzed DNA samples from a cohort of 32 unrelated patients with CMT type 1 who did not have the 1.5-Mb tandem duplication in 17p11.2-p12 for mutations within the PMP22 coding region. Molecular techniques included the polymerase chain reaction (PCR), heteroduplex analysis to detect point mutations, and direct nucleotide-sequence determination of amplified PCR products. Results. A 10-year-old boy was identified with a point mutation in PMP22, which resulted in the substitution of cysteine for serine in a putative transmembrane domain of PMP22. Analysis of family members revealed that the PMP22 point mutation arose spontaneously and segregated with the CMT type 1 phenotype in an autosomal dominant pattern. The patients with the PMP22 point mutation had clinical and electrophysiologic phenotypes that were similar to those of patients with the 1.5-Mb duplication. Conclusions. The PMP22 gene has a causative role in CMT type 1. Either a point mutation in PMP22 or a duplication of the region including the PMP22 gene can result in the disease phenotype.
引用
收藏
页码:96 / 101
页数:6
相关论文
共 50 条
  • [21] THE PERIPHERAL MYELIN GENE PMP-22/GAS-3 IS DUPLICATED IN CHARCOT-MARIE-TOOTH DISEASE TYPE-1A
    VALENTIJN, LJ
    BOLHUIS, PA
    ZORN, I
    HOOGENDIJK, JE
    VANDENBOSCH, N
    HENSELS, GW
    STANTON, VP
    HOUSMAN, DE
    FISCHBECK, KH
    ROSS, DA
    NICHOLSON, GA
    MEERSHOEK, EJ
    DAUWERSE, HG
    VANOMMEN, GJB
    BAAS, F
    NATURE GENETICS, 1992, 1 (03) : 166 - 170
  • [22] THE PERIPHERAL MYELIN PROTEIN GENE PMP-22 IS CONTAINED WITHIN THE CHARCOT-MARIE-TOOTH DISEASE TYPE-1A DUPLICATION
    TIMMERMAN, V
    NELIS, E
    VANHUL, W
    NIEUWENHUIJSEN, BW
    CHEN, KL
    WANG, S
    OTHMAN, KB
    CULLEN, B
    LEACH, RJ
    HANEMANN, CO
    DE JONGHE, P
    RAEYMAEKERS, P
    VANOMMEN, GJB
    MARTIN, JJ
    MULLER, HW
    VANCE, JM
    FISCHBECK, KH
    VAN BROECKHOVEN, C
    NATURE GENETICS, 1992, 1 (03) : 171 - 175
  • [23] SNP analysis of PMP22 and predicted PMP22 targeting mir genes in Charcot-Marie-Tooth neuropathy type 1A
    Nam, S. H.
    Lee, H. J.
    Shin, B. L.
    Choi, B. O.
    Chung, K. W.
    MOLECULAR BIOLOGY OF THE CELL, 2013, 24
  • [24] Compound heterozygous PMP22 deletion mutations causing severe Charcot-Marie-Tooth disease type 1
    Abe, Akiko
    Nakamura, Kazuyuki
    Kato, Mitsuhiro
    Numakura, Chikahiko
    Honma, Tomomi
    Seiwa, Chizuru
    Shirahata, Emi
    Itoh, Aiko
    Kishikawa, Yumiko
    Hayasaka, Kiyoshi
    JOURNAL OF HUMAN GENETICS, 2010, 55 (11) : 771 - 773
  • [25] Squalenoyl siRNA PMP22 nanoparticles, a potent therapy for Charcot-Marie-Tooth disease type 1A
    Boutary, Suzan
    Massaad-Massade, Liliane
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2021, 26 (03) : 363 - 364
  • [26] Severe phenotypes in a Charcot-Marie-Tooth 1A patient with PMP22 triplication
    Kim, Sung Min
    Lee, Jinho
    Yoon, Bo Ram
    Kim, Ye Jin
    Choi, Byung-Ok
    Chung, Ki Wha
    JOURNAL OF HUMAN GENETICS, 2015, 60 (02) : 103 - 106
  • [27] Post-transcriptional microRNA repression of PMP22 dose in severe Charcot-Marie-Tooth disease type 1
    Pipis, Menelaos
    Won, Seongsik
    Poh, Roy
    Efthymiou, Stephanie
    Polke, James M.
    Skorupinska, Mariola
    Blake, Julian
    Rossor, Alexander M.
    Moran, John J.
    Munot, Pinki
    Muntoni, Francesco
    Laura, Matilde
    Svaren, John
    Reilly, Mary M.
    BRAIN, 2023, 146 (10) : 4025 - 4032
  • [28] Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A
    Suzan Boutary
    Marie Caillaud
    Mévidette El Madani
    Jean-Michel Vallat
    Julien Loisel-Duwattez
    Alice Rouyer
    Laurence Richard
    Céline Gracia
    Giorgia Urbinati
    Didier Desmaële
    Andoni Echaniz-Laguna
    David Adams
    Patrick Couvreur
    Michael Schumacher
    Charbel Massaad
    Liliane Massaad-Massade
    Communications Biology, 4
  • [29] Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A
    Boutary, Suzan
    Caillaud, Marie
    El Madani, Mevidette
    Vallat, Jean-Michel
    Loisel-Duwattez, Julien
    Rouyer, Alice
    Richard, Laurence
    Gracia, Celine
    Urbinati, Giorgia
    Desmaele, Didier
    Echaniz-Laguna, Andoni
    Adams, David
    Couvreur, Patrick
    Schumacher, Michael
    Massaad, Charbel
    Massaad-Massade, Liliane
    COMMUNICATIONS BIOLOGY, 2021, 4 (01)
  • [30] PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models
    Zhao, Hien Tran
    Damle, Sagar
    Ikeda-Lee, Karli
    Kuntz, Steven
    Li, Jian
    Mohan, Apoorva
    Kim, Aneeza
    Hung, Gene
    Scheideler, Mark A.
    Scherer, Steven S.
    Svaren, John
    Swayze, Eric E.
    Kordasiewicz, Holly B.
    JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (01): : 359 - 368